$223.27
0.25% today
NYSE, Mar 13, 06:45 pm CET
ISIN
US0758871091
Symbol
BDX

Becton, Dickinson & Stock price

$223.82
-2.03 0.90% 1M
-11.68 4.96% 6M
-3.05 1.34% YTD
-14.00 5.89% 1Y
-26.54 10.60% 3Y
+8.78 4.08% 5Y
+84.36 60.50% 10Y
NYSE, Closing price Wed, Mar 12 2025
-1.10 0.49%
ISIN
US0758871091
Symbol
BDX
Sector

Key metrics

Market capitalization $64.27b
Enterprise Value $82.19b
P/E (TTM) P/E ratio 37.18
EV/FCF (TTM) EV/FCF 28.00
EV/Sales (TTM) EV/Sales 3.98
P/S ratio (TTM) P/S ratio 3.11
P/B ratio (TTM) P/B ratio 2.55
Dividend yield 1.70%
Last dividend (FY24) $3.80
Revenue growth (TTM) Revenue growth 5.89%
Revenue (TTM) Revenue $20.64b
EBIT (operating result TTM) EBIT $2.92b
Free Cash Flow (TTM) Free Cash Flow $2.94b
Cash position $830.00m
EPS (TTM) EPS $6.02
P/E forward 25.54
P/S forward 2.94
EV/Sales forward 3.77
Short interest 1.02%
Show more

Is Becton, Dickinson & a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,808 stocks worldwide.

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Becton, Dickinson & forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Becton, Dickinson & forecast:

Buy
84%
Hold
16%

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
20,640 20,640
6% 6%
100%
- Direct Costs 11,279 11,279
1% 1%
55%
9,361 9,361
16% 16%
45%
- Selling and Administrative Expenses 3,012 3,012
26% 26%
15%
- Research and Development Expense 1,243 1,243
2% 2%
6%
5,106 5,106
14% 14%
25%
- Depreciation and Amortization 2,190 2,190
2% 2%
11%
EBIT (Operating Income) EBIT 2,916 2,916
27% 27%
14%
Net Profit 1,748 1,748
39% 39%
8%

In millions USD.

Don't miss a Thing! We will send you all news about Becton, Dickinson & directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Becton, Dickinson & Stock News

Neutral
Seeking Alpha
2 days ago
Becton, Dickinson and Company (NYSE:BDX ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst [Call Starts Abruptly] Everyone for joining us today. We are so pleased to h...
Positive
Seeking Alpha
6 days ago
Barron's New-Year (NY) Roundtable (RT) selections published in three issues 1/13-27/2025, listed 34 dividend picks as the best of 2025. Analysts predict top picks like AdvanSix, Applied Materials, and Salesforce could net significant returns, with an average gain estimate of 28.85%. Two standout "safer" stocks, AT&T and Annaly Capital, meet the dogcatcher ideal, offering high yields relative to...
Neutral
Seeking Alpha
8 days ago
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overvalued stocks with detailed metrics and fair value estimates. My quality scoring system uses six indicators, each worth 5 points, for a maximum score of 30, categorizing stocks from Exceptional to Inf...
More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office United States
CEO Thomas Polen
Employees 74,000
Founded 1897
Website www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today